Moreover, doing so lays the foundations for safe introduction of the single-dose 8-aminoquinoline therapy called tafenoquine, a product now approaching regulatory registration and clinical availability.85 That product will also require excluding G6PD-deficient patients in order to realise its enormous promise as a new tool against vivax malaria. The gene discussed is G6PD; the disease is Plasmodium vivax malaria.